These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35112344)

  • 1. Differential sleep/wake response and sex differences following acute suvorexant, MK-1064 and zolpidem administration in the rTg4510 mouse model of tauopathy.
    Keenan RJ; Daykin H; Chu J; Cornthwaite-Duncan L; Allocca G; Hoyer D; Jacobson LH
    Br J Pharmacol; 2022 Jul; 179(13):3403-3417. PubMed ID: 35112344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orexin 2 receptor antagonism sex-dependently improves sleep/wakefulness and cognitive performance in tau transgenic mice.
    Keenan RJ; Daykin H; Metha J; Cornthwaite-Duncan L; Wright DK; Clarke K; Oberrauch S; Brian M; Stephenson S; Nowell CJ; Allocca G; Barnham KJ; Hoyer D; Jacobson LH
    Br J Pharmacol; 2024 Jan; 181(1):87-106. PubMed ID: 37553894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects.
    Struyk A; Gargano C; Drexel M; Stoch SA; Svetnik V; Ma J; Mayleben D
    Eur Neuropsychopharmacol; 2016 Oct; 26(10):1649-56. PubMed ID: 27554636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators.
    Gotter AL; Garson SL; Stevens J; Munden RL; Fox SV; Tannenbaum PL; Yao L; Kuduk SD; McDonald T; Uslaner JM; Tye SJ; Coleman PJ; Winrow CJ; Renger JJ
    BMC Neurosci; 2014 Sep; 15():109. PubMed ID: 25242351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Sleep, Memory, and Cellular Pathological Features of Tauopathy, Including the NLRP3 Inflammasome, after Chronic Administration of Trazodone in rTg4510 Mice.
    de Oliveira P; Cella C; Locker N; Ravindran KKG; Mendis A; Wafford K; Gilmour G; Dijk DJ; Winsky-Sommerer R
    J Neurosci; 2022 Apr; 42(16):3494-3509. PubMed ID: 35273086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts.
    Svetnik V; Snyder ES; Tao P; Scammell TE; Roth T; Lines C; Herring WJ
    Sleep; 2018 Jan; 41(1):. PubMed ID: 29112763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual effects of low dose of suvorexant, zolpidem, and ramelteon in healthy elderly subjects: A randomized double-blind study.
    Uemura SI; Imanishi A; Terui Y; Park I; Satake M; Han G; Shioya T; Kanbayashi T; Nishino S
    Neuropsychopharmacol Rep; 2022 Sep; 42(3):288-298. PubMed ID: 35748642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.
    Sun H; Kennedy WP; Wilbraham D; Lewis N; Calder N; Li X; Ma J; Yee KL; Ermlich S; Mangin E; Lines C; Rosen L; Chodakewitz J; Murphy GM
    Sleep; 2013 Feb; 36(2):259-67. PubMed ID: 23372274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration.
    Holton CM; Hanley N; Shanks E; Oxley P; McCarthy A; Eastwood BJ; Murray TK; Nickerson A; Wafford KA
    Alzheimers Res Ther; 2020 Jul; 12(1):84. PubMed ID: 32669112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased Orexin Receptor 1 mRNA Expression in the Locus Coeruleus in Both Tau Transgenic rTg4510 and Tau Knockout Mice and Accompanying Ascending Arousal System Tau Invasion in rTg4510.
    Keenan RJ; Oberrauch S; Bron R; Nowell CJ; Challis LM; Hoyer D; Jacobson LH
    J Alzheimers Dis; 2021; 79(2):693-708. PubMed ID: 33361602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse potential assessment of the new dual orexin receptor antagonist daridorexant in recreational sedative drug users as compared to suvorexant and zolpidem.
    Ufer M; Kelsh D; Schoedel KA; Dingemanse J
    Sleep; 2022 Mar; 45(3):. PubMed ID: 34480579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study.
    Schoedel KA; Sun H; Sellers EM; Faulknor J; Levy-Cooperman N; Li X; Kennedy WP; Cha JH; Lewis NM; Liu W; Bondiskey P; McCrea JB; Panebianco DL; Troyer MD; Wagner JA
    J Clin Psychopharmacol; 2016 Aug; 36(4):314-23. PubMed ID: 27253658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation.
    Beuckmann CT; Ueno T; Nakagawa M; Suzuki M; Akasofu S
    Sleep; 2019 Jun; 42(6):. PubMed ID: 30923834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of methamphetamine on actigraphy-based sleep parameters in female rhesus monkeys: Orexin receptor mechanisms.
    Borgatti DA; Rowlett JK; Berro LF
    Drug Alcohol Depend; 2024 Jun; 259():111285. PubMed ID: 38636173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MK-8719, a Novel and Selective
    Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
    J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct effects of IPSU and suvorexant on mouse sleep architecture.
    Hoyer D; Dürst T; Fendt M; Jacobson LH; Betschart C; Hintermann S; Behnke D; Cotesta S; Laue G; Ofner S; Legangneux E; Gee CE
    Front Neurosci; 2013; 7():235. PubMed ID: 24368893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model.
    Bailey RM; Howard J; Knight J; Sahara N; Dickson DW; Lewis J
    Mol Neurodegener; 2014 Jan; 9():8. PubMed ID: 24428919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
    Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.